Safety and efficacy of recombinant botulinum toxin type A (Eveotox®) in patients with post-stroke upper limb spasticity: Results from a Phase Ib/II clinical trial.
ToxiconJul 23, 2026 (epub)
Rongrong Lu, Lingjing Jin, Jianzhong Xiong et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase Ib/II randomized controlled trial assessed the safety and efficacy of recombinant botulinum toxin type A (Eveotox®) in adults with post-stroke upper limb spasticity. The study found a significant reduction in the Modified Ashworth Scale (MAS) score of the primary target muscle group at Week 4 compared to placebo, indicating effective spasticity management.
Key findings
- At Week 4, the MAS score significantly decreased in the Eveotox® group compared to placebo.
- The Physician's Global Assessment score improved significantly in the Eveotox® group at Week 4.
- The treatment was generally well tolerated with a low incidence of antibodies observed.
Why it matters
Effective management of post-stroke upper limb spasticity is crucial for improving patient function and quality of life. This study suggests that recombinant botulinum toxin type A may offer a reliable treatment option with favorable safety and efficacy profiles.